Pirofsky B, Reid R H, Bardana E J, Baker R L
Postgrad Med J. 1976;52(5 Suppl):112-7.
The therapeutic effect of goat anti-human thymocyte antiserum globulin (ATG) was assessed in 10 patients with myasthenia gravis. Prolonged, low dose therapy was used with 1-0--1-6 grams protein administered intramuscularly over a 28-73 day period. Varying degrees of therapeutic response were noted in 8 patients. Fllow-up examinations for over 5 years have been maintained and relapse rates determined. The clinical criteria for aptients selection and characteristics of therapeutic response are presented.
对10例重症肌无力患者评估了山羊抗人胸腺细胞抗血清球蛋白（ATG）的治疗效果。采用延长的低剂量疗法，在28至73天内肌肉注射1.0至1.6克蛋白质。8例患者出现不同程度的治疗反应。进行了超过5年的随访检查并确定了复发率。介绍了患者选择的临床标准和治疗反应特征。
